Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 6/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.49 |
| ▸ | SCN1A | P35498 | 2/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135561 | 0.87 | LMNA (0.50) | CDK2GSK3BWDR5 | |
| SCHEMBL16135684 | 0.84 | KCNQ3 (0.44) | WDR5 | |
| SCHEMBL16135708 | 0.84 | P2RX7 (0.48) | SCN3AP2RX7SCN1ASCN5ASCN9A | |
| SCHEMBL16135709 | 0.83 | P2RX7 (0.47) | SCN3AP2RX7SCN1ASCN5ASCN9A | |
| SCHEMBL16135549 | 0.81 | ROCK2 (0.48) | ROCK2WDR5 | |
| SCHEMBL27931735 | 0.78 | P2RX7 (0.51) | SCN3AP2RX7SCN1ASCN5ASCN9A | |
| SCHEMBL16135541 | 0.78 | CHRM4 (0.43) | WDR5 | |
| SCHEMBL27931748 | 0.78 | L3MBTL1 (0.58) | SCN3AP2RX7SCN1ASCN5ASCN9A | |
| SCHEMBL16135566 | 0.77 | CHRM4 (0.50) | ROCK2CDK2GSK3BWDR5 | |
| SCHEMBL16135689 | 0.77 | LMNA (0.49) | CDK2GSK3BWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970124-B1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | UNIV LELAND STANFORD JUNIOR (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10227304-B2 | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-11-09 | — | — | US | disclosed |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-11-09 | — | — | US | disclosed |
| US-9670162-B2 | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670162-B2 | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160107996-A1 | Mitochondrial Aldehyde Dehyrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-04-21 | — | — | US | disclosed |
| US-20160107996-A1 | Mitochondrial Aldehyde Dehyrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-04-21 | — | — | US | disclosed |
| WO-2014160185-A2 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107996-A1 | Mitochondrial Aldehyde Dehyrogenase-2 Modulators and Methods of Use Thereof | ALDH2, ALDH5A1, SHMT2 | SCN3A 2437/4885P2RX7 4468/4885SCN1A 2314/4885 |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | ALDH2, ALDH5A1, DLD | SCN3A 1822/4885P2RX7 4062/4885SCN1A 1508/4885 |
| US-10227304-B2 | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | ALDH2, ALDH5A1, DLD | SCN3A 1822/4885P2RX7 4062/4885SCN1A 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.